Acalabrutinib alone or in combination with rituximab for follicular lymphoma: An open‐label study
Acalabrutinib is a selective, second-generation Bruton tyrosine kinase inhibitor. In this open-label, parallel-group study, patients with relapsed/refractory (R/R) follicular lymphoma (FL) were randomised to either acalabrutinib monotherapy or acalabrutinib plus rituximab. An additional cohort of patients with treatment-naive (TN) FL received only the acalabrutinib-rituximab combination. Acalabrutinib-rituximab was well tolerated and active in R/R and TN FL; in the TN cohort the overall response rate was 92.3% with most remissions lasting over 4 years. Acalabrutinib monotherapy was also well tolerated and active in R/R FL. These results support further study of acalabrutinib alone and in combination with rituximab in FL.
Authors
- Rebecca Champion
- Sonali M. Smith (ORCID: https://orcid.org/0000-0002-9893-4949)
- Parameswaran Venugopal (ORCID: https://orcid.org/0000-0002-7518-9579)
- Paolo Strati (ORCID: https://orcid.org/0000-0002-7445-1459)
- Peter Martin (ORCID: https://orcid.org/0000-0001-7813-1551)
- Morton Coleman (ORCID: https://orcid.org/0000-0002-8516-2513)
- Kara Miller
- Andrew Wood (ORCID: https://orcid.org/0000-0001-6863-0824)
- Beth Christian
Institutions
- AstraZeneca (United Kingdom) (GB)
- Rush University Medical Center (US)
- NewYork–Presbyterian Hospital (US)
- The University of Texas MD Anderson Cancer Center (US)
- Norton Healthcare (US)
- Cornell University (US)
- New York Hospital Queens (US)
- University of Chicago Medical Center (US)
- Presbyterian Hospital (US)
- Clinical Research Associates (US)
- AstraZeneca (United States) (US)
- Weill Cornell Medicine (US)
- The Ohio State University (US)
Publication Details
- Journal
- British Journal of Haematology
- Published
- 2024-09-22
- DOI
- https://doi.org/10.1111/bjh.19787
- Citations
- 2
- Primary Topic
- Chronic Lymphocytic Leukemia Research
- Type
- article
- Field-Weighted Citation Impact
- 0.88
Funders
- AstraZeneca